Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05383833 · ClinicalTrials.gov registry record · NA

Creatine to Augment Bioenergetics in Alzheimer's

A NA study of Alzheimers Disease, sponsored by University of Kansas Medical Center.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT05383833 is a NA study of Alzheimers Disease that has completed, run by University of Kansas Medical Center. The registered enrollment target is 20 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05383833, a NA study of Alzheimers Disease, has completed, sponsored by University of Kansas Medical Center.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

By doing this study, researchers hope to see if creatine monohydrate is a helpful treatment for people with Alzheimer's disease.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Creatine Monohydrate

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2022-12-12
Est. Completion 2024-05-14
Phase NA

Sponsor

University of Kansas Medical Center

408 total trials

What the Registry Record Tells You About NCT05383833

The ClinicalTrials.gov registry entry for NCT05383833 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (100% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which Creatine Monohydrate is the first listed.

NCT05383833 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT05383833 about?

NCT05383833 is a clinical study titled "Creatine to Augment Bioenergetics in Alzheimer's". By doing this study, researchers hope to see if creatine monohydrate is a helpful treatment for people with Alzheimer's disease.

What is the current status of trial NCT05383833?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2022-12-12. Estimated completion is 2024-05-14.

What conditions does trial NCT05383833 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT05383833?

The interventions under investigation include: Creatine Monohydrate (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05383833?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05383833 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.